These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24193155)

  • 1. Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study.
    Adedokun OJ; Xu Z; Padgett L; Blank M; Johanns J; Griffiths A; Ford J; Zhou H; Guzzo C; Davis HM; Hyams J
    Inflamm Bowel Dis; 2013 Dec; 19(13):2753-62. PubMed ID: 24193155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.
    Hyams J; Damaraju L; Blank M; Johanns J; Guzzo C; Winter HS; Kugathasan S; Cohen S; Markowitz J; Escher JC; Veereman-Wauters G; Crandall W; Baldassano R; Griffiths A;
    Clin Gastroenterol Hepatol; 2012 Apr; 10(4):391-9.e1. PubMed ID: 22155755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical Benefit.
    Hyams JS; Chan D; Adedokun OJ; Padgett L; Turner D; Griffiths A; Veereman G; Heyman MB; Rosh JR; Wahbeh G; Strauss R
    Inflamm Bowel Dis; 2017 Dec; 23(12):2227-2237. PubMed ID: 29140944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
    Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
    Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H; Arai K; Kagimoto S; Kunisaki R; Hida N; Sato N; Yamada H; Nagano M; Susuta Y; Ozaki K; Kondo K; Hibi T
    BMC Pediatr; 2019 Oct; 19(1):351. PubMed ID: 31607268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
    Farkas K; Rutka M; Golovics PA; Végh Z; Lovász BD; Nyári T; Gecse KB; Kolar M; Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Malickova K; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Palatka K; Lakatos PL; Lukas M; Molnár T
    J Crohns Colitis; 2016 Nov; 10(11):1273-1278. PubMed ID: 27106537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.
    Moore H; Dolce P; Devas N; Baldassano R; Martinelli M
    United European Gastroenterol J; 2020 May; 8(4):425-435. PubMed ID: 32213038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis.
    Brandse JF; Mathôt RA; van der Kleij D; Rispens T; Ashruf Y; Jansen JM; Rietdijk S; Löwenberg M; Ponsioen CY; Singh S; van den Brink GR; D'Haens GR
    Clin Gastroenterol Hepatol; 2016 Feb; 14(2):251-8.e1-2. PubMed ID: 26545802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis.
    Vande Casteele N; Jeyarajah J; Jairath V; Feagan BG; Sandborn WJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1814-1821.e1. PubMed ID: 30613004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.
    Magro F; Lopes S; Silva M; Coelho R; Portela F; Branquinho D; Correia L; Fernandes S; Cravo M; Caldeira P; Sousa HT; Patita M; Lago P; Ramos J; Afonso J; Redondo I; Machado P; Cornillie F; Lopes J; Carneiro F;
    J Crohns Colitis; 2019 Oct; 13(11):1387-1393. PubMed ID: 30989180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.
    Magnusson MK; Strid H; Isaksson S; Bajor A; Lasson A; Ung KA; Öhman L
    J Crohns Colitis; 2015 Jan; 9(1):56-65. PubMed ID: 25518051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.
    De Vos M; Dewit O; D'Haens G; Baert F; Fontaine F; Vermeire S; Franchimont D; Moreels T; Staessen D; Terriere L; Vander Cruyssen B; Louis E;
    J Crohns Colitis; 2012 Jun; 6(5):557-62. PubMed ID: 22398050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
    Iwasa R; Yamada A; Sono K; Furukawa R; Takeuchi K; Suzuki Y
    BMC Gastroenterol; 2015 Aug; 15():103. PubMed ID: 26271624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.
    Dreesen E; Verstockt B; Bian S; de Bruyn M; Compernolle G; Tops S; Noman M; Van Assche G; Ferrante M; Gils A; Vermeire S
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1937-1946.e8. PubMed ID: 29704680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
    Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ;
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.
    Fasanmade AA; Adedokun OJ; Olson A; Strauss R; Davis HM
    Int J Clin Pharmacol Ther; 2010 May; 48(5):297-308. PubMed ID: 20420786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of induction therapy with infliximab in children with moderate to severe ulcerative colitis: a multi-center study.
    Szychta M; Wiernicka A; Dądalski M; Landowski P; Klincewicz B; Karolewska-Bochenek K; Czaja-Bulsa G; Jarocka-Cyrta E; Korczowski B; Sladek M; Kierkus J
    Dev Period Med; 2016; 20(3):205-211. PubMed ID: 27941190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.